JP6383787B2 - 卵巣癌の治療方法 - Google Patents

卵巣癌の治療方法 Download PDF

Info

Publication number
JP6383787B2
JP6383787B2 JP2016521841A JP2016521841A JP6383787B2 JP 6383787 B2 JP6383787 B2 JP 6383787B2 JP 2016521841 A JP2016521841 A JP 2016521841A JP 2016521841 A JP2016521841 A JP 2016521841A JP 6383787 B2 JP6383787 B2 JP 6383787B2
Authority
JP
Japan
Prior art keywords
antibody
seq
fra
subject
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016521841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529484A5 (cg-RX-API-DMAC7.html
JP2016529484A (ja
Inventor
シュバイツァー、チャールズ
オシャネシー、ダニエル、ジョン
Original Assignee
モルフォテック， インコーポレイテッド
モルフォテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モルフォテック， インコーポレイテッド, モルフォテック， インコーポレイテッド filed Critical モルフォテック， インコーポレイテッド
Publication of JP2016529484A publication Critical patent/JP2016529484A/ja
Publication of JP2016529484A5 publication Critical patent/JP2016529484A5/ja
Application granted granted Critical
Publication of JP6383787B2 publication Critical patent/JP6383787B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016521841A 2013-06-20 2014-06-20 卵巣癌の治療方法 Expired - Fee Related JP6383787B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361837543P 2013-06-20 2013-06-20
US61/837,543 2013-06-20
PCT/US2014/043402 WO2014205342A2 (en) 2013-06-20 2014-06-20 Methods for treatment of ovarian cancer

Publications (3)

Publication Number Publication Date
JP2016529484A JP2016529484A (ja) 2016-09-23
JP2016529484A5 JP2016529484A5 (cg-RX-API-DMAC7.html) 2017-08-03
JP6383787B2 true JP6383787B2 (ja) 2018-08-29

Family

ID=52105530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016521841A Expired - Fee Related JP6383787B2 (ja) 2013-06-20 2014-06-20 卵巣癌の治療方法

Country Status (8)

Country Link
US (2) US20160311921A1 (cg-RX-API-DMAC7.html)
EP (1) EP3011013A4 (cg-RX-API-DMAC7.html)
JP (1) JP6383787B2 (cg-RX-API-DMAC7.html)
AU (1) AU2014284212B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015031950A2 (cg-RX-API-DMAC7.html)
CA (1) CA2914237A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015017950A (cg-RX-API-DMAC7.html)
WO (1) WO2014205342A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
KR102700777B1 (ko) * 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
WO2019099374A2 (en) * 2017-11-14 2019-05-23 University Of Virginia Patent Foundation Compositions and methods for making and using bispecific antibodies
US11873335B2 (en) 2018-03-13 2024-01-16 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
MX2022007798A (es) * 2019-12-23 2022-07-19 Eisai R&D Man Co Ltd Metodo de produccion de conjugado de anticuerpo-farmaco a base de eribulina.
CN117741149A (zh) * 2024-02-19 2024-03-22 卡秋(江苏)生物科技有限公司 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851332A (en) 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
US6351666B1 (en) 1998-02-27 2002-02-26 Biofield Corp. Method and apparatus for sensing and processing biopotentials
JP2002521743A (ja) 1998-07-16 2002-07-16 イメージアイディー リミティド 画像識別・配送システム
JP3952599B2 (ja) 1998-07-16 2007-08-01 松下電器産業株式会社 映像表示装置および映像表示方法
US6694090B1 (en) 1998-07-20 2004-02-17 Thomson Licensing S.A. Method and apparatus for dynamically overriding a ratings limit during playback of a digital program
EP1038257B2 (en) 1998-07-21 2008-10-08 Nxp B.V. System for the transmission of data from a data carrier to a station by means of at least one other auxiliary carrier signal
IT1303624B1 (it) 1998-07-22 2000-11-15 Techint Spa Dispositivo per elettrodeposizione a cella circonferenziale a flussidifferenziati.
DE19833226C1 (de) 1998-07-23 2000-04-20 Steuler Industriewerke Gmbh Niederschlagsrohrbündel für Naßelektrofilter
CA2338369C (en) 1998-07-24 2005-04-05 Yoshino Kogyosho Co., Ltd. Vessel equipped with a manual pump
CN1106227C (zh) 1998-07-24 2003-04-23 宝洁公司 具有带有改进的汲取管的抽吸分取器的内置袋型包装物
IT1301872B1 (it) 1998-07-24 2000-07-07 Abb Adda S P A Dispositivo di comando e controllo di interruttori di alta e mediatensione
DE19833340A1 (de) 1998-07-24 2000-02-10 Karlsruhe Forschzent Wurmförmiger Arbeitsmechanismus
WO2000005435A2 (en) 1998-07-24 2000-02-03 Ce Resources Pte Ltd. Array electrophoretic apparatus
WO2003094929A2 (en) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
EP1910821B1 (en) * 2005-06-24 2013-02-20 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
US8986650B2 (en) * 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
CA2673717A1 (en) * 2006-12-20 2008-06-26 J-C Health Care Ltd. Method for administration of pegylated liposomal doxorubicin
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
ES2780192T3 (es) * 2010-11-05 2020-08-24 Eisai Inc Folato receptor alfa como marcador diagnóstico y de pronóstico para cánceres que expresan folato receptor alfa
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
MX362514B (es) * 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.

Also Published As

Publication number Publication date
AU2014284212B2 (en) 2019-09-12
WO2014205342A2 (en) 2014-12-24
EP3011013A4 (en) 2017-03-15
WO2014205342A3 (en) 2015-04-23
US20190202930A1 (en) 2019-07-04
EP3011013A2 (en) 2016-04-27
AU2014284212A1 (en) 2015-12-17
CA2914237A1 (en) 2014-12-24
JP2016529484A (ja) 2016-09-23
WO2014205342A4 (en) 2015-06-04
US20160311921A1 (en) 2016-10-27
BR112015031950A2 (pt) 2017-07-25
MX2015017950A (es) 2016-05-10

Similar Documents

Publication Publication Date Title
US20190202930A1 (en) Methods for treatment of ovarian cancer
RU2718780C2 (ru) Способы лечения рака легкого
JP6057718B2 (ja) ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
US20230064677A1 (en) Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
US20240084037A1 (en) Protein biomarker and uses thereof
US20140341893A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
KR20150119406A (ko) Ｃａｉｘ 계층화 기반 암 치료
JP6122948B2 (ja) 胃癌の治療のための方法
ES2939143T3 (es) Biomarcadores para una politerapia que comprende lenvatinib y everolimus
KR20180013878A (ko) 렌바티닙 및 에베로리무스를 포함하는 병용 요법을 위한 생체표지
WO2019064073A1 (en) USE OF CA125 FOR PREDICTING ANTI-MESOTHELIC TREATMENT OF MESOTHELIOMES
NZ624444B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
HK1198063A (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151216

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20151216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180806

R150 Certificate of patent or registration of utility model

Ref document number: 6383787

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees